Enhancing the predictive validity of frog embryo teratogenesis assay -: Xenopus (FETAX)

Enhancing the predictive validity of frog embryo teratogenesis assay -: Xenopus (FETAX)
复制标题

DOI:
10.1002/jat.848
复制
发表时间:
2002-05-01
影响因子:
3.3
通讯作者:
Paul, RR
Paul, RR
中科院分区:
医学4区
文献类型:
--
作者:
Fort, DJ;Paul, RR

文献摘要

被引文献

相似文献

Frog Embryo teratgenesis assay - xenopus (FETAX)是一项为期4天的替代性发育毒性试验,旨在预先筛选化学物质和环境混合物。用于FETAX结果评分的方法侧重于确定由给定测试材料引起的特征异常,用于评估先前验证工作的结果。特征性异常是由暴露于给定的测试材料引起的,并由浓度与引起的反应和反应严重程度变化之间的关系决定。使用这种方法消除了改变数值终点的非特异性影响,减少了实验室内的可变性,减少了模棱两可的测试结果(灰色区域)的数量,有助于确定与致畸原暴露相关的特定综合征,在某些情况下,增加了FETAX的可预测性。为了评估这种方法,使用特征畸形标准重新评估了一项产生相对高度模糊FETAX结果的12种化合物验证研究。评估数据的可重复性、可预测性和可变性。这项研究的结果表明,这种评分方法增加了可重复性,测试终点的精度和可预测性。版权所有:John Wiley Sons, Ltd。
Frog Embryo Teratogenesis Assay-Xenopus (FETAX) is a 4-day, alternative developmental toxicity assay designed to pre-screen chemicals and environmental mixtures. An approach used in the scoring of FETAX results, which focuses on the determination of characteristic abnormalities induced by a given test material, was used to evaluate results from previous validation efforts. Characteristic abnormalities are induced specifically by exposure to a given test material and are determined by the relationship between concentration and the response induced and the change in severity of response. Use of this approach eliminates non-specific effects that alter numerical endpoints, reduces intralaboratory variability, reduces the number of equivocal test results (gray area), helps to determine specific syndromes associated with teratogen exposure and, in some instances, increases the predictability of FETAX. In an effort to evaluate this approach, a 12-compound validation study that produced a relatively high degree of equivocal FETAX results was re-evaluated using the characteristic malformation criteria. Data were evaluated for repeatability, predictability and variability. Results from this study indicated that this scoring approach increased repeatability, test endpoint precision and predictability. Copyright (C) 2002 John Wiley Sons, Ltd.